- Published
- 11 December 2021
- Journal article
High-dose budesonide for early COVID-19
- Authors
- Source
- The Lancet
Abstract
We were encouraged by the results of the PRINCIPLE trial, which in vulnerable individuals showed inhaled budesonide to confer a non-significant –25% (95% CI –45 to 3) relative reduction in the composite coprimary endpoint of hospital admission or death, with the number needed to treat being 50. Notably, the study had 90% power to detect a 50% reduction in the composite endpoint. The investigators appear to have attributed any protective effects of budesonide to its local glucocorticoid activity in the lung.
Rights
COVID-19 Resource Centre Access the latest 2019 novel coronavirus disease (COVID-19) content from across The Lancet journals as it is published. https://www.thelancet.com/action/clickThrough?id=103216&url=%2Fcoronavirus&loc=%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%2821%2902440-5%2Ffulltext&pubId=60648183&placeholderId=101488&productId=101912
Cite as
Lipworth, B., Chan, R. & Misirovs, R. 2021, 'High-dose budesonide for early COVID-19', The Lancet, 398(10317), pp. 2147-2147. https://doi.org/10.1016/S0140-6736(21)02440-5